跳转至内容
Merck
所有图片(1)

Key Documents

390238

Sigma-Aldrich

Camptothecin, 10-Hydroxy-, Camptotheca acuminata

A cell-permeable powerful DNA topoisomerase I inhibitor.

别名:

Camptothecin, 10-Hydroxy-, Camptotheca acuminata, 10-Hydroxycamptothecin, HCPT

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C20H16N2O5
CAS号:
分子量:
364.35
分類程式碼代碼:
12352200

品質等級

化驗

≥95% (HPLC)

形狀

powder

製造商/商標名

Calbiochem®

儲存條件

OK to freeze

顏色

pale yellow

溶解度

DMSO: 5 mg/mL

運輸包裝

ambient

儲存溫度

2-8°C

InChI

1S/C20H16N2O5/c1-2-20(26)14-7-16-17-11(5-10-6-12(23)3-4-15(10)21-17)8-22(16)18(24)13(14)9-27-19(20)25/h3-7,23,26H,2,8-9H2,1H3

InChI 密鑰

HAWSQZCWOQZXHI-UHFFFAOYSA-N

一般說明

A cell-permeable powerful DNA topoisomerase I inhibitor. Reduces DNA synthesis in vitro in murine hepatoma cells. Has selective inhibitory effect on the phosphorylation of histone H1 and H3, but less effect on other histones.
A cell-permeable, powerful DNA topoisomerase I inhibitor. Reduces DNA synthesis in vitro in murine hepatoma cells. Inhibits the proliferation of hepatoma HepG2, Bcl-7402 and Bcl-7404 cells in a dose-dependent manner. Has selective inhibitory effect on the phosphorylation of histones H1 and H3, but is less effective on other histones.

生化/生理作用

Cell permeable: yes
Primary Target
DNA topoisomerase I
Product does not compete with ATP.
Reversible: no

警告

Toxicity: Irritant (B)

重構

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

其他說明

Zhang, X.W., et al. 1999. Anticancer Drugs.10, 569.
Ling, Y.H., et al. 1993. Anticancer Res. 13, 1613.
Wani, M.C., and Wall, M.E. 1969. J. Org.Chem.34, 1364.

法律資訊

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

象形圖

Skull and crossbonesHealth hazard

訊號詞

Danger

危險聲明

危險分類

Acute Tox. 3 Oral - Muta. 1B

儲存類別代碼

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

其他客户在看

Slide 1 of 1

1 of 1

Mengfan Tang et al.
Nucleic acids research, 49(13), 7476-7491 (2021-07-02)
Poly (ADP-ribose) polymerase inhibitor (PARPi)-based therapies initially reduce tumor burden but eventually lead to acquired resistance in cancer patients with BRCA1 or BRCA2 mutation. To understand the potential PARPi resistance mechanisms, we performed whole-genome CRISPR screens to discover genetic alterations

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门